The seed round was co-led by Creator Fund and LocalGlobe to help the biotech startup move its egg-quality treatment toward the clinic.
"Ovo Labs’ mission is to make the dream of parenthood a reality for millions of couples who struggle to conceive. By helping to increase the number of viable eggs, we aim to extend the reproductive window, empowering more couples to have children at a time that feels right to them. Ovo Labs’ technology also offers a potential solution for declining birth rates, which is a trend observed in many countries worldwide."
The agritech startup closed a round backed by biotope, Planetary Impact Ventures, and PINC to accelerate its digital tool development.
"Soil is the foundation of our food system, but modern agriculture has strained its health. The soil microbiome holds the key to restoring fertility, resilience, and reducing reliance on synthetic inputs. By unlocking its potential, we can help farmers produce food sustainably while regenerating the land for future generations."
The financing from Sofinnova Partners and Old College Capital will support the launch of precision fibrosis therapeutics.
"Launching Forth Tx through Sofinnova’s biotech accelerator has allowed us to translate years of our multiomics-driven research into precision therapies that we hope will transform patients’ lives. Fibrosis is an area of huge unmet medical need, and I’m delighted to be working with Alex and the Sofinnova team, as well as OCC, to deliver potent, new treatments for patients with fibrosis."
— Neil Henderson, Chair of Tissue Repair and Regeneration at the University of Edinburgh
General Catalyst led the financing alongside a syndicate of new and existing investors to support the developer of antibody-based therapeutics.
"KnotBodies represent a potential breakthrough biologic drug modality, delivering greater potency, selectivity, and durability. We believe they will provide transformational new therapeutic options for ion channel- and GPCR-driven diseases across a wide range of therapeutic areas with a remaining high unmet medical need. The calibre of our international investor syndicate validates our approach, and I would like to welcome our new investors to Maxion and thank our existing investors for their continued support."
